Skip Nav Destination
Drug development challenges in polycythemia vera
Oral idasanutlin in patients with polycythemia vera
Issue Archive
Table of Contents
BLOOD COMMENTARIES
CLINICAL TRIALS AND OBSERVATIONS
Drug development challenges in polycythemia vera
Clinical Trials & Observations
PLENARY PAPER
IMMUNOBIOLOGY AND IMMUNOTHERAPY
Comprehensive viromewide antibody responses by systematic epitope scanning after hematopoietic cell transplantation
There is a on this article in this issue.
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
Oral idasanutlin in patients with polycythemia vera
Clinical Trials & Observations
LYMPHOID NEOPLASIA
IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia
There is a on this article in this issue.
MYELOID NEOPLASIA
PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ acute myeloid leukemia
There is a on this article in this issue.
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
LETTERS TO BLOOD
Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of β-thalassemia
There is a on this article in this issue.
In vitro evaluation of factor IX as novel treatment for factor XI deficiency
There is a on this article in this issue.
BLOOD WORK
-
Cover Image
Cover Image
![issue cover]()
Phosphatidylinositol 3-kinase δ inhibitor (iPI3K-δ)–resistant murine Eμ-TCL1 tumors stained with forkhead box O1 (FOXO1) and DAPI (4′,6-diamidino-2-phenylindole). Notice the FOXO1 localization in the nucleus upon exposure to iPI3K-δ, which leads to an increase in insulin-like growth factor 1 receptor expression and downstream signaling. See the article by Scheffold et al on page 534.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
